AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents
| Image |  |
|---|---|
| Description | scientific article published on 22 December 2010 |
| Author/s |
author: Segev Barak Guy Griebel |
| Publication date | December 22, 2010 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |